U.S. antitrust enforcers give Roche approval to buy Spark Therapeutics

WASHINGTON (Reuters) – Swiss drugmaker Roche (S:) has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics (O:), the Federal Trade Commission said on Monday, clearing the way for the Swiss drugmaker’s push into treating rare diseases including hemophilia A.

The FTC approved the deal, which was originally announced in February, without requiring any asset sales to ensure that the planned merger complies with antitrust law, the agency said in a statement.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.